Originally published In Press as doi:10.1074/jbc.M102344200 on August 31, 2001
J. Biol. Chem., Vol. 276, Issue 45, 42138-42145, November 9, 2001
Human Glutathione Transferase P1-1 and Nitric Oxide Carriers
A NEW ROLE FOR AN OLD ENZYME*
Mario Lo
Belloab,
Marzia
Nuccetellia,
Anna
M.
Caccuria,
Lorenzo
Stellacl,
Michael W.
Parkerde,
Jamie
Rossjohndf,
William J.
McKinstrydg,
Alessia F.
Mozzih,
Giorgio
Federicii,
Francesca
Polizioa,
Jens Z.
Pedersenaj, and
Giorgio
Ricciak
From the Departments of a Biology, c Chemistry, and
h Internal Medicine, University of Rome "Tor Vergata," 00133 Rome, Italy, the d Biota Structural Biology Laboratory, St.
Vincent's Institute of Medical Research, Fitzroy, Victoria 3065, Australia, and the i Children's Hospital
l Istituto di Ricerca e Cura a Carattere Scientifico
"Bambino Gesù" 00165, Rome, Italy
Received for publication, March 15, 2001, and in revised form, August 30, 2001
 |
ABSTRACT |
S-Nitrosoglutathione
and the dinitrosyl-diglutathionyl iron complex are involved in the
storage and transport of NO in biological systems. Their interactions
with the human glutathione transferase P1-1 may reveal an additional
physiological role for this enzyme. In the absence of GSH,
S-nitrosoglutathione causes rapid and stable S-nitrosylation of both the Cys47 and
Cys101 residues. Ion spray ionization-mass spectrometry
ruled out the possibility of S-glutathionylation and
confirms the occurrence of a poly-S-nitrosylation in GST
P1-1. S-Nitrosylation of Cys47 lowers the
affinity 10-fold for GSH, but this negative effect is minimized by a
half-site reactivity mechanism that protects one
Cys47/dimer from nitrosylation. Thus, glutathione
transferase P1-1, retaining most of its original activity, may act as a
NO carrier protein when GSH depletion occurs in the cell. The
dinitrosyl-diglutathionyl iron complex, which is formed by
S-nitrosoglutathione decomposition in the presence of
physiological concentrations of GSH and traces of ferrous ions, binds
with extraordinary affinity to one active site of this dimeric enzyme
(Ki < 10
12 M) and
triggers negative cooperativity in the vacant subunit (Ki = 10
9 M). The complex
bound to the enzyme is stable for hours, whereas in the free form and
at low concentrations, its life time is only a few minutes. ESR and
molecular modeling studies provide a reasonable explanation of this
strong interaction, suggesting that Tyr7 and enzyme-bound
GSH could be involved in the coordination of the iron atom. All of the
observed findings suggest that glutathione transferase P1-1, by means
of an intersubunit communication, may act as a NO carrier under
different cellular conditions while maintaining its well known
detoxificating activity toward dangerous compounds.
 |
INTRODUCTION |
Glutathione transferases (EC 2.5.1.18)
(GSTs)1 are a superfamily of
enzymes involved in the detoxication of the cell against toxic and
carcinogenic compounds (1). The human cytosolic GSTs are dimeric
proteins grouped into at least eight gene-independent classes (Alpha,
Kappa, Mu, Omega, Pi, Sigma, Theta, and Zeta) on the basis of their
amino acid sequence, substrate specificity, and immunological
properties (2-8). Their three-dimensional structures do not differ
significantly despite low sequence homology (9-12). Each subunit
contains a very similar binding site for GSH (G-site) and a second one
for the hydrophobic co-substrate (H-site). Slight structural
differences at the H-site confers a certain degree of substrate
selectivity. For a more detailed review on the molecular properties of
GSTs see Ref. 13.
The physiological role of GSTs does not appear unequivocal. A well
known function of GSTs is to promote the conjugation of the sulfur atom
of glutathione to an electrophilic center of endogenous and exogenous
toxic compounds, thereby increasing their solubility and excretion (1).
The Alpha class also displays a peroxidase activity with organic
peroxides (14). Because of the considerable level of expression of GSTs
in many tissues and their property to bind a number of large
hydrophobic compounds, a possible role of "ligandins" (ligand
carriers) has been also proposed (15). Recent advances suggest a role
for GST P1-1 in the regulation of Jun kinase protein (a
stress-activated protein that phosphorylates c-Jun) (16) and as a
"tissue" transglutaminase-specific substrate in neural cells
committed to apoptosis (17). It has also been reported that certain
GSTs (class Theta) may inhibit the proapoptotic action of Bax (18), and
the most recently discovered class Omega, GST O1-1, modulates calcium
channels, thus protecting mammalian cells from apoptosis induced by
Ca2+ mobilization (19). Thus, GSTs can be considered as
multi-functional enzymes devoted to various aspects of cell defense.
Notwithstanding this versatility, GSTs have never been considered to be
involved in the complex mechanisms of detoxification or storage of
nitric oxide. NO is formed in organisms from endogenous or exogenous
sources and triggers a number of cellular responses, including the
regulation of blood pressure, the relaxation of smooth muscle, and the
modulation of immunity (20, 21). In the central nervous system, NO is a
neuronal messenger and is possibly responsible for the development of
various diseases (22-25). NO has a very short life time in the cell,
and its stabilization and transport are promoted by specific NO
carriers of low molecular mass, which are formed by the interaction of
nitric oxide with ferrous ions (dinitrosyl-iron complexes (DNIC))
(26-28) or with GSH (S-nitrosoglutathione (GSNO)) (29-32).
DNIC bind to proteins like albumin forming paramagnetic NO-Fe-protein
complexes that can be detected by ESR spectroscopy (33). Similar
complexes, known as 2.03 complexes, because of the g value
of their characteristic ESR spectra, have been observed in cells and
tissues exposed to NO, but nothing is known about the proteins involved
(34-37). Recently, kinetic studies showed that both GSNO and
dinitrosyl-diglutathionyl-iron complex (DNDGIC) are competitive
inhibitors of GSTs, and they have been proposed as activity modulators
of these enzymes (38, 39). Starting from these preliminary findings, we
have now investigated the interaction of these compounds with GST P1-1,
using ESR spectroscopy, site-directed mutagenesis, mass spectrometry,
and molecular modeling. Our results reveal a surprising and
sophisticated mode of interaction suggestive of a new role for this
enzyme in the cell as a NO reservoir or NO scavenger protein.
 |
EXPERIMENTAL PROCEDURES |
Expression Plasmids and Site-directed Mutagenesis--
The
plasmid pGST-1, producing large amounts of recombinant wild-type GST
P1-1 in the cytoplasm of Escherichia coli, has been described previously (40). The expression plasmid p18Seq-1, reported
previously (41), was used to generate the single-stranded DNA template
to be used for site-directed mutagenesis of Cys47 and
Cys101 residues, according to the method described by
Kunkel et al. (42) with minor modifications.
Protein Expression and Purification--
Native and mutant GST
P1-1 enzymes were produced as described previously (40, 41). Briefly,
TOP 10 E. coli cells harboring plasmid pGST-1 or plasmid
expressing Cys47 and Cys101 mutant enzymes
(pGST-A47 and pGST-A101) were grown in LB medium containing 100 µg/ml
ampicillin and 50 µg/ml streptomycin. The synthesis of GST was
induced by the addition of 0.2 mM
isopropyl-1-thio-
-galactopyranoside when the absorbance at 600 nm
was 0.5. Eighteen hours after induction, the cells were harvested by
centrifugation and lysed as described previously (40). Native and GST
mutant enzymes were purified by affinity chromatography on immobilized
glutathione (43). After affinity purification, the native and the
mutant enzymes (C47A and C101A) were homogeneous as judged by
SDS-polyacrylamide gel electrophoresis (44). Protein concentration was
determined by the method of Lowry et al. (45).
Kinetic Studies--
The enzymatic activities were determined
spectrophotometrically at 25 °C with 1-chloro-2,4-dinitrobenzene
(CDNB), as co-substrate, following the product formation at 340 nm,
= 9600 M
1 cm
1 (46).
Spectrophotometric measurements were performed in a double beam Uvicon
940 spectrophotometer (Kontron Instruments) equipped with a
thermostatted cuvette compartment. Initial rates were measured at 0.1-s
intervals for a total period of 12 s after a lag time of 5 s.
Enzymatic rates were corrected for the spontaneous reaction.
Apparent kinetic parameters kcat and
K
were
determined in 0.1 M potassium phosphate buffer, pH 6.5, and
0.1 mM EDTA, containing a fixed concentration of GSH (10 mM) and variable concentrations of CDNB (0.1-2
mM). The collected data were fitted to the Michaelis-Menten equation by nonlinear regression analysis using the GraphPad Prism (GraphPad Software, San Diego, CA). In a more accurate analysis, kinetic data were also fitted to Equation 1, which considers two distinct enzyme populations characterized by different
Km values for GSH.
|
(Eq. 1)
|
The apparent
K
was
also determined at fixed CDNB concentration (1 mM) and
variable GSH concentrations (from 0.02 to 20 mM). Kinetic
parameters reported in this paper represent the mean of at least three
different experimental data sets.
Preparation of GSNO--
GSNO was prepared as described
previously (47). Briefly, a few drops of HCl were added to a solution
containing equimolar amounts of GSH and sodium nitrite until pH 1.5 was
reached. After standing for 5 min at room temperature, the red GSNO was
neutralized with NaOH. GSNO displays an absorption maximum of 750 M
1 cm
1 at 332 nm and appears to
be stable for a few days at room temperature. Appropriate aliquots of
freshly synthesized compound were stored at
80 °C and used when
necessary, after checking their absorbance at 332 nm.
Synthesis of DNDGIC--
Dinitrosyl-diglutathionyl-iron complex
was synthesized according to the following procedure. Suitable amounts
of ferrous ions (FeSO4, ranging from 10 to 50 µM) were added to a mixture containing 20 mM
GSH and 2 mM GS-NO in 0.1 M phosphate buffer,
pH 7.4, and 25 °C. The synthesis of the complex was completed in the
first 15-20 min and gives an extinction coefficient of 3000 M
1 cm
1 at 403 nm.
Dinitrosyl-dicysteinyl-iron complex, under slightly different
conditions, displays an identical extinction coefficient at 395 nm
(48).
Interaction of GSNO with GST P1-1--
GST P1-1 or Cys mutant
enzymes (ranging from 0.03 to 1 mg/ml) were incubated with 2 mM GSNO in 0.1 M phosphate buffer, pH 7.4, at
25 °C. At various times aliquots were taken and assayed for
enzymatic activity with CDNB as co-substrate. In a different set of
experiments, 20 mM GSH was added to the mixture containing the above concentrations of GSNO and protein with or without 1 mM EDTA.
UV Difference Spectra--
Difference spectra were performed
with a double beam Uvicon 940 spectrophotometer (Kontron Instruments)
equipped with a thermostatted cuvette compartment. Spectral data of
free and bound DNDGIC complex were recorded in the range 290-500 nm at
25 °C at pH 7.4 using quartz cuvettes (1-cm light path).
Interaction of DNDGIC with GST P1-1--
Inhibition of GST P1-1
by DNDGIC was measured by incubating variable amounts of DNDGIC (from
0.5 to 9 µM) with 0.1 mg/ml (4.4 µM of
active sites) of GST P1-1. After 2 min 10-µl aliquots (final concentration of GST P1-1 is 44 nM active sites) were
assayed for activity at pH 6.5 (final volume, 1 ml) in the presence of 10 mM GSH and 1 mM CDNB. Thus, the final
concentration of DNDGIC in the activity sample ranged from 5 to 90 nM. In a second experimental set, GST P1-1 (44 nM of active sites) was incubated at pH 7.4 with variable
amounts of DNDGIC (from 0.1 to 22 µM). After 2 min the pH
was adjusted to 6.5, the GSH concentration was brought to a final
concentration of 10 mM, and 1 mM CDNB was then
added for activity measurement.
Electron Spin Resonance--
ESR spectra were recorded with an
ESP300 instrument (Bruker, Karlsruhe, Germany) operating at X-band
frequency. Low temperature measurements (100 K) were made using a
standard TE102-type cavity with samples in 3-mm-inner
diameter quartz tubes, whereas experiments performed at room
temperature were made using a high sensitivity TM110-type
cavity with samples contained in 1.10-mm-inner diameter capillary
tubes. ESR spectra were recorded at 20 mW microwave power and 1 G
modulation; for resolution of the hyperfine structure some spectra were
recorded using 0.2 G modulation.
Mass Spectrometry--
GST P1-1 (final concentration, 2.0 mg/ml)
was incubated with 2 mM GSNO, under the conditions reported
above, for 15 min. Thereafter, it was passed through a Sephadex G-25
column, equilibrated with distilled water, containing 0.1 mM EDTA, to remove any excess of reagent and used soon for
mass spectrometry studies. A sample of unmodified human GST P1-1 was
equilibrated in the same manner, before mass spectroscopic analysis.
The samples were diluted with 99% acetonitrile to give the final
solution of acetonitrile/water 50% + formic acid 0.2% (v/v). Mass
spectrometry spectra were collected in continuous flow mode by
connecting the built-in infusion pump directly to the ion spray probe.
Molecular masses of both unmodified and modified GST P1-1 enzymes were
determined using a Triple Quadrupole liquid chromatography/mass
spectrometry/mass spectrometry mass spectrometer Applied
Biosystem Sciex API 365 (Concord, Canada). The data were acquired and
processed using Mass Chrom 1.2 (Applied Biosystem Sciex, Concord,
Ontario, Canada), including BioMultiView 1.3.1 for mathematical
transformation of ion spray spectra to true mass scale.
Molecular Modeling--
Molecular modeling was performed on a
Silicon Graphics O2 work station using the software package
O (49). The model was based on the 1.9 Å resolution crystal structure
of human class Pi GST P1-1 in complex with GSH (50). A model of DNGIC
was constructed assuming tetrahedral geometry and metal-ligand
distances based on measurements from small molecule crystal structures
(51), with the topology and parameters files for the DNGIC complex
obtained using XPLO2D and refined using crystallography and NMR
system (52). It is not clear whether the complex adopts a
tetrahedral or octahedral (with two water ligands) configuration when
bound to the enzyme. However, either configuration will fit into the active site, and the same conclusions can be drawn from either model.
The DNGIC model was docked into the active site of the enzyme assuming
that the GSH ligand of DNGIC occupied the same site as the GSH ligand
in the crystal structure of the enzyme-GSH complex. It was immediately
noted that the hydroxyl moiety of Tyr7 was in covalent
bonding distance of the iron atom. A model of the complex covalently
bound via Tyr7 was constructed. The resultant model was
energy minimized with CNS (52). Initially harmonic restraints of 10 kcal/mol were applied to the protein atoms, but subsequently the
restraints were removed in the final stages of minimization. The final
energy minimized model exhibited no significant structural differences with the crystal structure of the enzyme. Graphic representation was
produced by the computer program MOLSCRIPT (53).
 |
RESULTS AND DISCUSSION |
Interaction of GSNO with GST P1-1 in the Absence of GSH--
GSNO
is a competitive inhibitor for GST P1-1 (38, 39), but in the absence of
GSH this compound also causes a time-dependent partial
inactivation of the enzyme. After 10 min of incubation, the activity is
reduced to about 70% of its initial value and remains unchanged even
after 1 h of incubation (Fig. 1).
The presence of 1 mM EDTA in the incubation mixture does
not affect significantly the extent and the rate of inactivation.
Treatment of the inactivated enzyme with 100 mM
1,4-dithiothreitol restores completely the original activity. The
modified enzyme does not follow strictly Michaelian kinetics and shows
an apparent Km value for GSH of 0.45 mM,
which is three times higher than in the native enzyme and accounts
completely for the observed loss of activity, using the standard GSH
concentration of 1 mM (46). Cys47 and
Cys101, the most reactive among the four cysteines of each
subunit (41, 54), are possible targets for the reversible modification
by GSNO. Titration of the protein sulfhydryls after 1 h of GSNO (2 mM, pH 7.4) treatment shows that three sulfhydryl
groups/dimer have been lost. The UV spectrum of the modified enzyme
(Fig. 1, inset) shows a maximum at 332 nm, which corresponds
to that found for the nitroso-thiol species (47). The amount of the
protein CysNO, calculated on the basis of an extinction value of 750 M
1 cm
1 at 332 nm (47), is 1.6 mol/subunit. When GSNO is reacted for 1 h with the C47S mutant
enzyme, no inactivation was observed, and two cysteines/dimer are
nitrosylated. Conversely, the C101A mutant only yields 1 mol of
CysNO/dimer. Thus, it appears that Cys47 and
Cys101 act as primary targets for a specific
S-nitrosylation by GSNO, but only the modification of
Cys47 decreases the enzyme activity. Furthermore, when this
residue is nitrosylated in one subunit, the second in the adjacent
subunit becomes less accessible. In fact, the kinetic data of the
modified enzyme can be fitted more convincingly to a kinetic scheme
involving two enzyme populations with different Km
values for GSH (see Equation 1). The best fit gives
Vmax1 = Vmax2 and Km
values for GSH of 0.2 mM and 1.2 mM,
respectively. This result is also consistent with two subunits with
different affinities in the same dimeric population. The observed
half-site reactivity of Cys47 compensates for the lowering
of the affinity for GSH (like that observed in the modified subunit)
and could reflect a self-preservation role of enzyme activity. This
behavior is not unusual for GST P1-1 and is reminiscent of the
nonequivalent reactivity of the two subunits of the horse GST
P1-1 in their reaction with sulfhydryl reagents (55).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Inactivation of GST P1-1 by GSNO. ,
GST P1-1 (0.1 mg/ml) was incubated with 2 mM GSNO in 0.1 M potassium phosphate buffer, pH 7.4, at 25 °C. At
various times the activity was measured at 340 nm in the presence of 1 mM GSH and 1 mM CDNB, as described under
"Experimental Procedures." After 60 min, 100 mM
1,4-dithiothreitol was added to the mixture. , same experiment with
C47A mutant enzyme. C101A mutant enzyme gives an inactivation pattern
similar to that of the native enzyme (not shown). Inset,
differential UV spectrum of GST P1-1 (1.2 mg/ml) after 60 min of
incubation with 2 mM GSNO, pH 7.4, and removal of the
excess of reagents by G-25 Sephadex chromatography. The reference
cuvette contained 1.2 mg/ml of native GST P1-1.
|
|
Mass Spectrometric Analysis of NO-modified GST P1-1--
To gain
direct evidence of S-nitrosylation of human GST P1-1 we have
carried out ion spray ionization-mass spectrometry of the modified GST
P1-1, and the results are shown in Fig.
2. Ion spray mass spectra of the
unmodified protein (Fig. 2a) showed two main peaks
corresponding to the molecular masses of 23,226 and 23,356 Da,
respectively. The former molecular mass corresponds to that calculated
from its cDNA, whereas the latter is due to the failed removal of
N-terminal methionine, and both are consistent with data reported
previously (40, 56). In the Fig. 2b, we observe two series
of peaks with mass increases of 30 ± 1 Da, in addition to the
unmodified proteins (23,226 and 23,356 Da, respectively), suggesting
nitrosylation of GST P1-1. In particular, it appears that the first
species (23,226 Da) exhibits molecular masses of M+ +30 and
M+ + 60, respectively; the second species (23,356 Da) shows the same mass increases of +30 ± 1 and +60 ± 1 Da
and, to lesser extent, a third peak with a mass increase of + 90 ± 1 Da. Thus, in accordance with the data reported above, these
spectra demonstrate the simultaneous presence of, at least, the mono-
and di-nitrosylated subunits, whereas the expected mass of about
M+ +305, for glutathionylated GST P1-1, was not found. The
presence of a third peak with a mass increase of + 90 ± 1 Da in
the species with N-terminal methionine requires further investigation
because it may be due also to a methionine oxidation. Further mass
spectrometry studies on Cys mutant enzymes will be made to unravel the
mechanism of GST P1-1 modification.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
Ion spray mass spectra of GST P1-1 and
GSNO-modified GST P1-1 recombinant proteins. Ion spray ionization
BioMultiView transformed spectrum of GST P1-1 (a) and
GSNO-modified GST P1-1 recombinant proteins (b).
|
|
Interaction of GSNO with GST P1-1 in the Presence of GSH--
It
is well known that saturating amounts of GSH protect from the chemical
modifications caused by thiol reagents. Cys47, located at
the end of the mobile helix-2, is exposed to the solvent only in the
apoenzyme, whereas it is buried in the holoenzyme (55, 57, 58). When
GSNO (2 mM) is incubated with 0.1 mg/ml GST P1-1 in the
presence of 20 mM GSH and 1 mM EDTA, no
inactivation can be observed within 1 h of incubation (Fig.
3). However, in the absence of EDTA, a
fast inactivation occurs that leaves 50% of the original activity
after 10 min of incubation (Fig. 3). Similar half-site inhibition is
observed at lower GST concentrations, but the extent of this phenomenon
is reduced by increasing the enzyme concentration. For example, at 1 mg/ml, it does not exceed 5% (Fig. 3). The cause of this inhibition
will be clarified below and likely depends on metal traces present in
the buffers.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 3.
Interaction of GSNO with GST P1-1 in the
presence of GSH. , GST P1-1 (0.1 mg/ml) was incubated at
25 °C with 20 mM GSH and 2 mM GSNO in 0.1 M potassium phosphate buffer, pH 7.4, and 1 mM
EDTA (25 °C). Variable amounts of GST P1-1 were incubated with 20 mM GSH and 2 mM GSNO in 0.1 M
potassium phosphate buffer, pH 7.4, without EDTA (25 °C). GST P1-1
concentrations were 0.03 mg/ml ( ); 0.06 mg/ml ( ); 0.1 mg/ml
( ); 0.5 mg/ml ( ); and 1 mg/ml ( ).
|
|
Dinitrosyl-Diglutathionyl Iron Complex Is Formed in the GSH-GSNO
System with Ferrous Ions--
When GSNO (2 mM) and GSH (20 mM) are incubated at 25 °C in the presence of
substoichiometric amounts of ferrous ions (10-50 µM), a
fast reaction occurs, signaled by the appearance of an UV absorption
peak, centered at about 400 nm, which is suggestive of the formation of
the dinitrosyl-diglutathionyl iron complex (48) (Fig.
4). Kinetics of this process cannot be
described satisfactorily by a simple mono-exponential function but fit
better to a two phase exponential function (Fig.
5). ESR spectra confirm the presence of a
paramagnetic species with ESR signals at
70 °C and 25 °C,
similar to those reported for other DNICs (26-33) (Fig.
6A). The appearance of
the paramagnetic complex parallels the UV spectral increase at 403 nm
(Fig. 5). After 20 min, 90% of the added ferrous ions is present as
DNDGIC, and this complex is stabilized up to 180 min. After this time,
a slow decomposition occurs, characterized by a t1/2
of about 90 min. Diluted DNDGIC solutions, synthesized by the
conventional procedures and without a NO-generating system, exhibit
very short half-lives (about 1 min at micromolar concentrations) (33). The protocol described here provides a convenient procedure for a
quantitative and stabilized preparation of DNDGIC, based on slow
release of NO by GSNO in the presence of physiological concentrations of GSH and substoichiometric iron. The apparent stability of DNDGIC is
likely due to a steady-state equilibrium coming from simultaneous decomposition and resynthesis of the complex.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
UV-visible spectral analysis of dinitrosyl
diglutathionyl iron complex. Curve a, GSNO (2 mM) and GSH (20 mM) were incubated in 0.1 M potassium phosphate buffer, pH 7.4, in the presence of 20 µM ferrous sulfate. The spectrum is recorded after 60 min
of incubation at 25 °C. The reference cuvette contained all
reagents except ferrous sulfate. Curve b, as in curve
a in the presence of 0.9 mg/ml of GST P1-1 (40 µM of active sites) both in the sample and
references cuvettes. Curve c, as in curve b
after G-25 Sephadex chromatography. The spectrum has been normalized to
an enzyme concentration of 0.9 mg/ml.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 5.
Kinetics of DNDGIC formation as observed by
UV and ESR data. a, , kinetics of DNDGIC formation
at pH 7.4 followed at 403 nm. DNDGIC was formed as reported in the
legend of Fig. 3. , the same experiment in the presence of 1 mg/ml
of GST P1-1, followed at 408 nm. b, the same experiments as
in a followed by means of ESR measurements.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 6.
ESR spectra. A, curve
a, GSNO (2 mM) and GSH (20 mM) were
incubated in 0.1 M potassium phosphate buffer, pH 7.4, in
the presence of 20 µM ferrous sulfate. The spectrum is
recorded after 60 min of incubation at 25 °C. Curve
b, the same incubation mixture as in curve a in the
presence of 1 mg/ml GST P1-1. Curve c, as in curve
b after G-25 Sephadex chromatography. Spectra were recorded at 77 K. B, spectrum of the free DNDGIC obtained as in
A without GST P1-1, recorded at 298 K.
|
|
Binding of DNDGIC to GST P1-1--
DNDGIC has been described as a
competitive inhibitor of GST P1-1 toward GSH (39), but a more careful
investigation reveals different and unexpected properties of
interaction with this enzyme. Substoichiometric amounts of DNDGIC yield
a degree of inhibition that corresponds exactly to an interaction of
1:1 active site-inhibitor. 50% of the original activity is reached
when the molar amount of DNDGIC corresponds to 50% of the active sites
(Fig. 7a). Increasing concentrations of DNDGIC (up to 4-fold excess over free active sites)
does not produce any further significant inhibition. This behavior can
be explained by a very strong interaction of the complex with one of
the two binding sites of the dimeric enzyme. By assuming that DNDGIC
causes competitive inhibition (39), a quantitative evaluation of the
dissociation constant for the DNDGIC-GST complex
(Ki) can be made observing that the 50% inactivated
enzyme maintains its half activity even at the high dilution of
10
9 M and in the presence of 10 mM GSH. This means that Ki must be
<1.5 × 10
12 M, which represents the
strongest interaction of a small compound with this enzyme. The second
G-site binds DNDGIC only at very much higher DNDGIC concentrations
(Fig. 7b). This second weaker interaction is characterized
by a Ki of 2.6 × 10
9
M. Considering the homodimeric structure of this enzyme,
this behavior is likely due to a strong negative cooperativity
triggered by the interaction of DNDGIC with the first subunit that
dramatically lowers the affinity of the vacant subunit. Structural
communication between subunits has been previously reported for GST
P1-1. It is well known that this enzyme has a latent cooperativity that becomes evident at extreme temperatures or by point mutation of crucial
residues (41, 59-61). The observed negative cooperativity mainly
involves the affinity for DNDGIC. In fact, the Km value for GSH of the vacant subunit (calculated in the half-inactivated enzyme) appears only slightly higher (0.35 mM) than that
shown by the native enzyme (0.15 mM), whereas the
Km value for CDNB is unchanged. Even in this case,
as observed for Cys47 nitrosylation, this behavior seems to
be a mechanism by which the enzyme protects itself against complete
inactivation because of DNDGIC binding.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 7.
Inhibition of GST P1-1 by DNDGIC.
a, variable amounts of DNDGIC, obtained after reaction of
GSNO, GSH, and ferrous ions as reported in text, were mixed with 0.1 mg/ml of GST P1-1. After 2 min 10-µl aliquots were assayed for
activity at pH 6.5 in the presence of 10 mM GSH and 1 mM CDNB (final volume, 1 ml; final concentration of GST
P1-1 is 44 nM active site; DNDGIC ranges from 5 to 90 nM). b, GST P1-1 (44 nM of active
sites) was incubated at pH 7.4 with variable amounts of DNDGIC (from
0.1 to 21 µM). After 2 min the pH was adjusted to 6.5, the GSH concentration was brought to a final concentration of 10 mM, and 1 mM CDNB was then added for activity
measurement.
|
|
The preliminary finding of a particular inhibition obtained by reacting
the enzyme with GSNO and GSH without the addition of exogenous iron
(Fig. 3) can be now rationalized. In fact, about 2 µM of
DNDGIC are formed using the spurious contaminating iron present in the
buffer. This low DNDGIC concentration (which will be confirmed by ESR
analysis) is enough to cause 50% inhibition when reacted with 0.1 mg/ml GST P1-1 (4.4 nmol/ml active site) or with lower enzyme
concentrations but not with 1 mg/ml enzyme concentration.
Competition with Serum Albumin--
DNDGIC binds to serum albumin
with high affinity, and this protein could be a reservoir of
S-nitrosylating species (33). Experiments of competition of
this protein with GST P1-1 may give an estimation of the relative
affinity of the two proteins against DNDGIC. We found that even 50 mg/ml of serum albumin does not affect at all the inhibition of 0.1 mg/ml of GST P1-1 because of the interaction with 2 µM of
DNDGIC, thus indicating that GST P1-1 has at least 500 times more
affinity than albumin for DNDGIC.
UV Spectral and Chemical Properties of DNIC Bound to GST
P1-1--
The UV spectrum of DNDGIC bound to the enzyme in the
presence of 20 mM GSH is similar but not identical to the
free species showing a slight red shift of the maximum at 408 nm and
with a less pronounced descending limb below 400 nm (Fig. 4). The
kinetics of DNDGIC formation is identical to that obtained in the
absence of enzyme, so GST P1-1 does not appear directly involved in the complex formation (Fig. 5). The complex is tightly bound to the enzyme
and remains associated to the enzyme even after a Sephadex G25
chromatography. The UV spectrum, observed after removal of the excess
of GSH, is broad (Fig. 4), but the subsequent addition of 20 mM GSH restores the descending limb below 400 nm (spectrum not shown). Thus, at least three similar but not identical DNDGIC forms
can be distinguished: the free mononuclear complex, the dinitrosyl-iron
complex bound to the enzyme in the presence of an excess of GSH, and a
third species obtained after removal of the excess of GSH. Notably, the
bound complex is stable for hours, and only 24 h after Sephadex
chromatography it spontaneously decomposes with the full recovery of
the enzyme activity. This represents a remarkable stabilization of the
bound complex when compared with its fast decomposition in the free
form (33).
It has been observed that the DNDGIC analogue dinitrosyl-dicysteinyl
iron complex binds tightly to bovine serum albumin, and one or both
cysteines involved in the iron complex may be replaced by protein
sulfhydryls or imidazoles (33). Titration of the amount of GSH involved
in the DNDGIC-GST P1-1 complex may be informative if a similar event
also occurs in GST P1-1. After binding of 44 µM DNDGIC to
88 µM GST P1-1 (final volume, 1 ml), the 50% inactivated enzyme was passed through a G-25 Sephadex column to remove the excess
of GSH. The enzyme displays the same half-activity, and the absorbance
at 403 nm confirms that about 40 nmol of the complex are still bound to
the enzyme. By adding 10 mM potassium cyanide, the spectral
band of DNDGIC at 403 nm disappears within a few minutes, and the
enzyme recovers the original full activity. In fact, CN
ions bind tightly to ferrous ions to give the extremely stable [Fe(CN)6]
4 complex
(Kinst = 10
35 at 291 K). After
cyanide treatment, the amount of free GSH has been titrated by adding 1 mM chloro-dinitrobenzene, a good co-substrate for GST, and
by measuring the amount of GS-DNB product formed (
= 9,600 M
1 cm
1 at 340 nm). The result
is 40 nmol of GSH detected, which corresponds exactly to 50% of that
expected if the bound DNDGIC would retain the same original
composition, thus indicating that one protein group replaced one GSH
molecule as iron ligand. Note that no GSH can be titrated without
previous potassium cyanide treatment, indicating complete removal of
the free GSH by gel chromatography. Both C47A and C101A mutant enzymes
give a very similar affinity and inhibition pattern by DNDGIC as the
native enzyme, so the Cys47 and Cys101
sulfhydryls are not involved in the stabilization of the iron complex
in the G-site.
ESR Studies--
At 77 K, DNDGIC shows an anisotropic ESR signal
of axial symmetry with g factors
g
= 2.04 and g
= 2.01 (Fig. 6A, trace a). When 20 µM DNDGIC are reacted with 44 µM GST P1-1
in the presence of 20 mM GSH, the spectrum at 77 K changes
slightly, indicating a shift toward a more defined axial symmetry (Fig.
6A, trace b). This spectrum is probably due to
the bound complex that still retains two GS
ions as iron
ligands. When the excess of GSH is removed by G25 Sephadex
chromatography, the ESR spectrum changes, with a
g
= 2.03 and
g
= 2.01, which corresponds to the monoglutathionyl complex (Fig.
6A, trace c), as confirmed by titration data (see
above). Readdition of 10 mM GSH to this species, shifts
again the ESR spectrum toward that shown by the authentic
diglutathionyl species (data not shown).
As expected, the anisotropy of the ESR signal of the bound complex does
not change significantly at 298 K, because of the slow tumbling rate of
the enzyme, whereas the free complex exhibits a quite isotropic signal
at g = 2.03 with multiple lines hyperfine structure
(Fig. 6B). Thus, as also indicated by UV analysis, three slightly different paramagnetic forms can be identified: the DNDGIC in
a free form, a DNDGIC bound to the GST P1-1 observed with GSH in
excess, and a third species in which one GSH molecule has probably been
replaced by a ligand provided by the protein or by a solvent molecule.
Molecular Modeling--
A view of the active site of the covalent
DNGIC (as obtained after removal of the excess GSH) is shown in Fig.
8. The final model shows that: (i) one of
the GSH ligands of DNDGIC can dock into the G-site and adopt the
canonical extended conformation seen in crystal structures of GST-GSH
complexes, (ii) Tyr7 is close enough to displace the other
GSH ligand to generate a stable enzyme-inhibitor complex, and (iii) the
NO moieties of the complex form van der Waal's interactions with
Ile104 and Tyr108. In addition there are
possible polar interactions with Tyr108 and the main chain
nitrogen of Gly205.

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 8.
Molecular modeling of DNGIC complex
bound to the active site of GST P1-1. Ribbon depiction of
the DNGIC enzyme complex. The close up view of the active site shows
key residues mentioned in the text. The iron atom is depicted as
an orange sphere, oxygen atoms are colored red,
nitrogen atoms are blue, sulfur atoms are yellow,
and carbon atoms are green. This figure was drawn using
MOLSCRIPT (53).
|
|
Concluding Remarks--
The findings reported above propose a
novel role for GST P1-1 in its interaction with physiological NO
carriers like GSNO and DNDGIC. In the absence of GSH, Cys47
and Cys101 represent the target residues for GSNO
interaction. The modification that occurs on these residues may be
restricted only to S-nitrosylation reaction. Different
modifications like S-glutathionylation of cysteines
residues, as observed in sarcoplasmic reticulum Ca-ATPase (62) and in
neurogranina/RC3 and neuromodulin/GAP-43 (63), can be ruled out on the
basis of mass spectrometry data. The nitrosylation of
Cys101 does not cause any activity perturbation, whereas
the modification of Cys47 decreases the affinity for GSH to
1.2 mM. However, when one Cys47 has been
nitrosylated, negative cooperativity masks the Cys47
residue of the second subunit, which remains unmodified even after
prolonged incubation times with GSNO. The nitrosylated enzyme displays
only slightly increased apparent Km value for GSH,
and then it retains a large fraction of its detoxicating potential
under physiological GSH concentrations. Thus, GST P1-1, in case of
cellular GSH depletion, may act directly as NO protein carrier without
detriment to its detoxicating activity. This corresponds to certain
cellular conditions such as strong oxidative stress, etc. Under normal
physiological conditions (millimolar GSH concentrations and metal
traces), GSNO does not react directly with the enzyme but through the
dinitrosyl-diglutathionyl iron complex. In fact, DNDGIC is rapidly
formed by GSNO decomposition at millimolar GSH concentrations and
micromolar ferrous ions. The interaction of this complex with GST P1-1
proceeds through a selected and sophisticated binding mechanism that
can be summarized as follows, on the basis of UV and ESR data and
molecular modeling: (i) In the presence of excess of GSH, DNDGIC binds
to the G-site of the enzyme. One of the two GSH molecules is stabilized
by the classical interactions of the G-site with its natural substrate;
the NO moieties are stabilized by van der Waal's and possible polar
interactions with protein atoms. All of these interactions account for
the very high affinity of the enzyme for this complex
(Ki < 10
12). When the excess of GSH
is removed, one of the two GSH molecules of the bound DNDGIC is lost
from the complex, and one protein residue, possibly the hydroxyl group
of Tyr7, is probably involved in the coordination of the
iron atom. (ii) Binding of DNDGIC triggers a structural modification in
the vacant subunit, which lowers its affinity for the complex by about
3 orders of magnitude (Ki = 2 ×10
9).
In conclusion, GST P1-1 appears to be a protein precisely designed for
a specific and sophisticated interaction with the natural compound
DNDGIC. Interestingly, serum albumin, previously suggested as a
physiological DNDGIC carrier, displays more than 500 times lower
affinity for this complex when compared with GST P1-1.
Because of the wide distribution of this cytosolic enzyme in several
tissues, this property suggests a new putative role for this enzyme in
the cell as a DNDGIC carrier protein. Interestingly, ESR studies
revealed that, in animal tissues, DNDGIC is bound to unknown proteins
with apparent molecular mass in the range 50-120 kDa (64). In some
cases, i.e. in the rat aorta (65), such complexes give ESR
signals different from DNDGIC in the free form, but very similar to
those seen after reaction with GST P1-1.
Our preliminary data suggest that other recently evolved GSTs,
i.e. Alpha and Mu isoenzymes, interact with DNDGIC like the Pi enzyme. However, the older bacterial enzyme, which is closer to the
ancestral precursor of GSTs and lacks the crucial Tyr residue in the
active site, does not interact with DNDGIC. Thus, we believe that the
present data, obtained for the human GST P1-1, may represent only a
first piece of a more complex scenario that can redefine and enlarge
the physiological role of the recently evolved GSTs.
 |
ACKNOWLEDGEMENT |
We thank very much Dr. Alyson Mitchell
(University of California, Davis) for helpful discussions about mass
spectrometry data.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
b
Supported in part by Ministero della Sanità Programma
di Ricerca Finalizzato 2000.
e
Australian Research Council Senior Research Fellow.
f
Wellcome Trust Senior Research Fellow in Medical Science in Australia.
g
National Health and Medical Research Council of Australian
Industry Fellow.
j
Supported in part by the European Training and Mobility of
Researchers Programme network "Non-Heme Iron Proteins."
k
Supported by Ministero dell'Università e
Ricerca Scientifica e Tecnologica Cofin 2000 and the National Research
Council of Italy (Target Project on Biotechnology). To whom
correspondence should be addressed. Tel.:
39-06-72594379; Fax: 39-06-2025450; E-mail: riccig@uniroma2.it.
Published, JBC Papers in Press, August 31, 2001, DOI 10.1074/jbc.M102344200
 |
ABBREVIATIONS |
The abbreviations used are:
GST, glutathione
S-transferase;
CDNB, 1-chloro-2,4-dinitrobenzene;
DNDGIC, dinitrosyl-diglutathionyl-iron complex(es);
DNGIC, dinitrosyl-glutathionyl-iron complex(es);
DNIC, dinitrosyl-iron complex(es);
ESR, electron spin resonance;
GSNO, S-nitrosoglutathione.
 |
REFERENCES |
| 1.
|
Jakoby, W. B.,
and Habig, W. H.
(1980)
in
Enzymatic Basis of Detoxification
(Jakoby, W. B., ed), Vol. 2
, pp. 63-94, Academic Press, New York
|
| 2.
|
Mannervik, B.,
Ålin, P.,
Guthenberg, C.,
Jensson, H.,
Tahir, M. K.,
Warholm, M.,
and Jörnvall, H.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
7202-7206[Abstract/Free Full Text]
|
| 3.
|
Meyer, D. J.,
Coles, B.,
Pemble, S. E.,
Gilmore, K. S.,
Fraser, G. M.,
and Ketterer, B.
(1991)
Biochem. J.
274,
409-414
|
| 4.
|
Buetler, T. M.,
and Eaton, D. L.
(1992)
Environ. Carcinog. Ecotoxicol. Rev.
10,
181-200
|
| 5.
|
Meyer, D. J.,
and Thomas, M. R.
(1995)
Biochem. J.
311,
739-742
|
| 6.
|
Pemble, S. E.,
Wardle, A. F.,
and Taylor, J. B.
(1996)
Biochem. J.
319,
749-754
|
| 7.
|
Board, P. G.,
Baker, R. T.,
Chelvanayagam, G.,
and Jermiin, L. S.
(1997)
Biochem. J.
328,
929-935
|
| 8.
|
Board, P. G.,
Coggan, M.,
Chelvanayagam, G.,
Easteal, S.,
Jermiin, L. S.,
Schulte, G. K.,
Danley, D. E.,
Hoth, L. R.,
Griffor, M. C.,
Kamath, A. V.,
Rosner, M. H.,
Chrunyk, B. A.,
Perregaux, D. E.,
Gabel, C. A.,
Geoghegan, K. F.,
and Pandit, J.
(2000)
J. Biol. Chem.
275,
24798-24806[Abstract/Free Full Text]
|
| 9.
|
Dirr, H. W.,
Reinemer, P.,
and Huber, R.
(1994)
Eur. J. Biochem.
220,
645-661[Medline]
[Order article via Infotrieve]
|
| 10.
|
Wilce, M. C. J.,
and Parker, M. W.
(1994)
Biochim. Biophys. Acta
205,
1-18
|
| 11.
|
Rossjohn, J.,
McKinstry, W. J.,
Oakley, A. J.,
Verger, D.,
Flanagan, J.,
Chelvanayagam, G.,
Tan, K.-L.,
Board, P. G.,
and Parker, M. W.
(1998)
Structure
6,
309-322[Medline]
[Order article via Infotrieve]
|
| 12.
|
Wilce, M. C. J.,
Board, P. G.,
Feil, S. C.,
and Parker, M. W.
(1995)
EMBO J.
14,
2133-2143[Medline]
[Order article via Infotrieve]
|
| 13.
|
Armstrong, R. N.
(1997)
Chem. Res. Toxicol.
10,
2-18[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Mannervik, B.
(1986)
Chem. Scripta
26,
281-284
|
| 15.
|
Litwach, G.,
Ketterer, B.,
and Arias, I. M.
(1971)
Nature
234,
466-477[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Adler, V.,
Yin, Z.,
Fuchs, S. Y.,
Benezra, M.,
Rosario, L.,
Tew, K. D.,
Pincus, M., R.,
Ardana, M.,
Henderson, C. J.,
Wolf, C. R.,
Davis, R. J.,
and Ronai, Z.
(1999)
EMBO J.
18,
1321-1334[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Piredda, L.,
Farrace, M. G.,
Lo Bello, M.,
Malorni, W.,
Melino, G.,
Petruzzelli, R.,
and Piacentini, M.
(1999)
FASEB J.
13,
355-364[Abstract/Free Full Text]
|
| 18.
|
Kampranis, S. C.,
Damianova, R.,
Atallah, M.,
Toby, G.,
Kondi, G.,
Tsichlis, P. N.,
and Mahkris, A. M.
(2000)
J. Biol. Chem.
275,
29207-29216[Abstract/Free Full Text]
|
| 19.
|
Dulhunty, A.,
Gage, P.,
Curtis, S.,
Chelvanayagam, G.,
and Board, P.
(2001)
J. Biol. Chem.
276,
3319-3323[Abstract/Free Full Text]
|
| 20.
|
Moncada, S.
(1994)
J. Hypertens.
12,
35-39
|
| 21.
|
Loscalzo, J.,
and Welch, G.
(1995)
Prog. Cardiovasc. Dis.
38,
87-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Moncada, S.,
Palmer, R. M. J.,
and Higgs, E. A.
(1991)
Pharmacol. Rev.
43,
109-142[Medline]
[Order article via Infotrieve]
|
| 23.
|
Tamir, S.,
and Tannenbaum, S. R.
(1996)
Biochim. Biophys. Acta
1288,
31-36
|
| 24.
|
Mey, C.
(1998)
Curr. Med. Res. Opin.
14,
187-202[Medline]
[Order article via Infotrieve]
|
| 25.
|
Rubanyi, G. M.
(1999)
in
Endothelial Cell Research Series
(Rubanyi, G. M., ed), Vol. 5
, Berlex Biosciences, Richmond, CA
|
| 26.
|
Vanin, A. F.,
Stukan, R. A.,
and Manukhina, E. B.
(1996)
Biochim. Biophys. Acta
1295,
5-12[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Vedernikov, Y. P.,
Mordvintcev, P. I.,
Malenkova, I. V.,
and Vanin, A. F.
(1992)
Eur. J. Pharmacol.
211,
313-317[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Ueno, T.,
and Yoshimura, T.
(2000)
Jpn. J. Pharmacol.
82,
95-101[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Hogg, N.,
Singh, R. J.,
and Kalyanaraman, B.
(1996)
FEBS Lett.
382,
223-228[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Kluge, I.,
Gutteck-Amsler, U.,
Zollinger, M.,
and Do, K. Q.
(1997)
J. Neurochem.
69,
2599-2607[Medline]
[Order article via Infotrieve]
|
| 31.
|
Myers, P. R.,
Minor, R. L., Jr.,
Guerra, R., Jr.,
Bates, J. N.,
and Harrison, D. G
(1990)
Nature
345,
161-163[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Stamler, J. S.
(1994)
Cell
78,
931-936[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Boese, M.,
Mordvintcev, P. I.,
Vanin, A. F.,
Busse, R.,
and Mulsch, A.
(1995)
J. Biol. Chem.
272,
29244-29249
|
| 34.
|
Lancaster, J. R., Jr.,
and Hibbs, J. B., Jr.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
1223-1227[Abstract/Free Full Text]
|
| 35.
|
Pellat, C.,
Henry, Y.,
and Drapier, J.-C.
(1990)
Biochem. Biophys. Res. Commun.
166,
119-125[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Drapier, J.-C.,
Pellat, C.,
and Henry, Y.
(1991)
J. Biol. Chem.
266,
10162-10167[Abstract/Free Full Text]
|
| 37.
|
Lancaster, J. R., Jr.,
Langrehr, J. M.,
Bergonia, H. A.,
Murase, N.,
Simmons, N.,
and Hoffman, R. A.
(1992)
J. Biol. Chem.
267,
10994-10998[Abstract/Free Full Text]
|
| 38.
|
Clark, A. G.,
and Debnam, P.
(1988)
Biochem. Pharmacol.
37,
3199-3201[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Keese, M. A.,
Bose, M.,
Mulsch, A.,
Shirmer, R. H.,
and Becker, K.
(1997)
Biochem. Pharmacol.
54,
1307-1313[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Battistoni, A.,
Mazzetti, A. P.,
Petruzzelli, R.,
Muramatzu, M.,
Ricci, G.,
Federici, G.,
and Lo Bello, M.
(1995)
Protein Expression Purif.
6,
579-587[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Lo Bello, M.,
Battistoni, A.,
Mazzetti, A. P.,
Board, P. G.,
Muramatzu, M.,
Federici, G.,
and Ricci, G.
(1995)
J. Biol. Chem.
270,
1249-1253[Abstract/Free Full Text]
|
| 42.
|
Kunkel, T. A.,
Bebenek, K.,
and McClary, J.
(1990)
Methods Enzymol.
204,
125-139
|
| 43.
|
Simmons, P. C.,
and Van der Jagt, D. L.
(1977)
Anal. Biochem.
82,
334-341[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Lowry, O. H.,
Rosebrough, N. J.,
Farr, A. L.,
and Randall, R.
(1951)
J. Biol. Chem.
193,
265-275[Free Full Text]
|
| 46.
|
Habig, W. H.,
and Jakoby, W. B.
(1981)
Methods Enzymol.
77,
398-405[Medline]
[Order article via Infotrieve]
|
| 47.
|
Park, J. W.
(1988)
Biochem. Biophys. Res. Commun.
152,
916-920[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Mulsh, A.,
Mordvintcev, P.,
Vanin, A. F.,
and Busse, R.
(1991)
FEBS Lett.
294,
252-256[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Jones, T. A.,
Zou, J.-Y.,
Cowan, S. W.,
and Kjeldgaard, M.
(1991)
Acta Crystallogr. Sect. A
47,
110-119
|
| 50.
|
Oakley, A. J.,
Lo Bello, M.,
Battistoni, A.,
Ricci, G.,
Rossjohn, J.,
Villar, H. O.,
and Parker, M. W.
(1997)
J. Mol. Biol.
274,
84-100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Harding, M. M.
(1999)
Acta Crystallogr. Sect. D Biol. Crystallogr.
55,
1432-1443[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Brünger, A. T.,
Adams, P. D.,
Clore, G. M.,
DeLano, W. L.,
Gros, P.,
Grosse-Kunstleve, R. W.,
Jiang, J.-S.,
Kuszewski, J.,
Nilges, M.,
Pannu, N. S.,
Read, R. J.,
Rice, L. M.,
Simonson, T.,
and Warren, G. L.
(1998)
Acta Crystallogr. Sect. D Biol. Crystallogr.
54,
905-921[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Kraulis, P. J.
(1991)
J. Appl. Crystallogr.
24,
946-950[CrossRef]
|
| 54.
|
Ricci, G.,
Del Boccio, G.,
Pennelli, A.,
Lo Bello, M.,
Petruzzelli, R.,
Caccuri, A. M.,
Barra, D.,
and Federici, G.
(1991)
J. Biol. Chem.
266,
21409-21415[Abstract/Free Full Text]
|
| 55.
|
Ricci, G.,
Del Boccio, G.,
Pennelli, A.,
Whitehead, E. P.,
and Federici, G.
(1989)
J. Biol. Chem.
264,
5462-5467[Abstract/Free Full Text]
|
| 56.
|
Mitchell, A.,
Zheng, J.,
Hammock, B.,
Lo Bello, M.,
and Jones, D.
(1998)
Biochemistry
37,
6752-6759[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Del Boccio, G.,
Pennelli, A.,
Whitehead, E. P.,
Lo Bello, M.,
Petruzzelli, R.,
Federici, G.,
and Ricci, G.
(1991)
J. Biol. Chem.
266,
13777-13782[Abstract/Free Full Text]
|
| 58.
|
Stella, L.,
Nicotra, M.,
Ricci, G.,
Rosato, N.,
and Di Iorio, E. E.
(1999)
Proteins
37,
1-9[Medline]
[Order article via Infotrieve]
|
| 59.
|
Caccuri, A. M.,
Antonini, G.,
Ascenzi, P.,
Nicotra, M.,
Nuccetelli, M.,
Mazzetti, A. P.,
Federici, G.,
Lo Bello, M.,
and Ricci, G.
(1999)
J. Biol. Chem.
274,
19276-19280[Abstract/Free Full Text]
|
| 60.
|
Ricci, G.,
Lo Bello, M.,
Caccuri, A. M.,
Pastore, A.,
Nuccetelli, M.,
Parker, M. W.,
and Federici, G.
(1995)
J. Biol. Chem.
270,
1243-1248[Abstract/Free Full Text]
|
| 61.
|
Lo Bello, M.,
Nuccetelli, M.,
Chiessi, E.,
Lahm, A.,
Mazzetti, A. P.,
Battistoni, A.,
Caccuri, A. M.,
Oakley, A. J.,
Parker, M. W.,
Tramontano, A.,
Federici, G.,
and Ricci, G.
(1998)
J. Mol. Biol.
284,
1717-1725[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Viner, R. I.,
Williams, T. D.,
and Schoneich, C.
(1999)
Biochemistry
38,
12408-12415[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Li, J.,
Huang, F. L.,
and Huang, K-P.
(2001)
J. Biol. Chem.
276,
3098-3105[Abstract/Free Full Text]
|
| 64.
|
Vanin, A. F.,
Osipov, A. N.,
Kubrina, L. N.,
Burbaev, D. S.,
and Nalbandyan, R. M.
(1975)
Stud. Biophys.
49,
13-25
|
| 65.
|
Kleschyov, A. L.,
Muller, B.,
Keravis, T.,
Stoeckel, M.-E.,
and Stoclet, J.-C.
(2000)
Am. J. Physiol.
279,
H2743-H2751
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg